55 results about "Urological Disorders" patented technology

An external stimulator adapted to be inductively coupled with an implanted lead-receiver is designed to deliver neuromodulation therapy for disorders including depression, migraine, partial complex epilepsy, generalized epilepsy, involuntary movement disorders, dementia, obsessive compulsive disorders, urinary incontinence, neurogenic/psychogenic pain and bladder control. The external stimulator containing limited number of predetermined programs packaged into the stimulator, giving the patient or caretaker a way to adjust the therapy within confined limits, or turn the device off. The pre-packaged programs contain unique combination of pulse amplitude, pulse width, frequency of stimulation, and on-off time. The programs are capable of being modified with a programming station connected to the pulse generator with a RS232-C serial connection.

An apparatus and method of use are disclosed to treat urological disorders. The biocompatible device includes a handle, needle, dilator and sling assembly configured to be minimally invasive and provide sufficient support to the target site. In addition, the configuration of the sling assembly also allows the sling to be adjusted during and/or after implantation. The device and treatment procedure are highly effective and produce little to no side effects or complications. Further, operative risks, pain, infections and post operative stays are reduced, thereby improving patient quality of life.

An implantable article and method of use are disclosed to treat urological disorders. The biocompatible device includes a sling assembly configured to be minimally invasive and provide sufficient support to the target site. In addition, the configuration of the sling assembly also allows the position of the sling to be permanently changed during and/or after implantation.

A minimally invasive surgical instrument for placing an implantable article about a tubular tissue structure is disclosed. The surgical instrument is particularly useful for treating urological disorders such as incontinence. Surgical methods using the novel instrument are also described.

A method and system for providing pulsed electrical stimulation to sacral nerves and/or its branches, to provide therapy for urinary/fecal incontinence and other urological disorders. The stimulation system comprising implanted and external components. The pulsed electrical stimulation may be provided using a system which is one from a group comprising: a) an implanted stimulus-receiver with an external stimulator; b) an implanted stimulus-receiver comprising a high value capacitor for storing charge, used in conjunction with an external stimulator; c) a programmer-less implantable pulse generator (IPG) which is operable with an external magnet; d) a programmable implantable pulse generator; e) a combination implantable device comprising both a stimulus-receiver and a programmable IPG; and f) an implantable pulse generator (IPG) comprising a rechargeable battery. In one embodiment, the external components such as the programmer or external stimulator may comprise telemetry means for interrogation or programming of the implanted device from a remote location, over a wide area network.

A method and system for neuromodulation therapy for urinary incontinence and urological disorders comprises an implantable lead stimulus-receiver, and an external stimulator-transmitter having a power source, controlling circuitry, and predetermined programs. The stimulator-transmitter further includes a primary coil which inductively transfers electrical signals to the lead-receiver, which is also in electric contact with the sacral nerves. The external stimulator-transmitter emits electrical pulses to stimulate the sacral plexus according to a predetermined program. In one mode of operation, the operator may program one of the predetermined programs, in another mode, the electrical parameters may be “custom” programmed for the patient, and stored in the memory.

The disclosure describes a wireless urodynamic monitoring system with an automated voiding diary feature. The system senses and records urodynamic information in response to a user command or in response to detection of the onset of a voiding event. The urodynamic information obtained over a series of voiding events forms an automated voiding diary that is useful in diagnosis of urological disorders. An implantable monitor obtains the urodynamic information and either records the information locally or transmits the information to an external controller via a wireless telemetry link. In some embodiments, the external controller may include a loop recorder for recording urodynamic information obtained by the implantable monitor over an extended period of time.

A method and system for providing electrical pulses for neuromodulating sacral nerves of a patient utilizing an implantable stimulator. The implantable stimulator comprising a pulse generator module and a stimulus receiver module for coupling with an external stimulator. Control circuitry ensures selective operation of one pulse generator module. The external stimulator comprises a telemetry module for remotely activating (or de-activating) programs over the internet, to arrive at the optimal program for each patient. Once the optimal “dose” is titrated using the external stimulator, the implanted pulse generator can then be programmed to such parameters. The external stimulator in conjunction with the implanted stimulus receiver can override the implanted pulse generator, to provide extra dose of therapy or to conserve the implanted battery. The external stimulator is also networked to other computers. The external programmer may also comprise a global positioning system (GPS) module for determining patient location.

It has been discovered that cytokines, chemokines, and growth factors in urine are biomarkers indicative of urological disorders including interstitial cystitis/painful bladder syndrome and overactive bladder syndrome. Preferred chemokine biomarkers are CCL2, CCL4 (MIP-1β), CCL11, CXCL1 (GRO-α), sCD40L, IL-12p70/p40, IL-5, sIL-2Rα, IL-6, IL-10, IL-8, and EGF. The concentration of one or more of these chemokines in an urine sample can be used to assist in the diagnosis of urological disorders. Methods for evaluating the effectiveness of treatments for urological disorders and for assessing the severity of urological disorders are also provided.

Some implementations provide a method for treating urological disorders in a patient, the method including: placing an introducer into a patient's body through an incision site on the patient's body, the patient suffering from an urological disorder; placing an implantable wireless device into an inner lumen of the introducer, the implantable wireless device suitable to fit into the inner lumen and configured to receive electromagnetic energy non-inductively from a source located outside the patient's body; through the inner lumen of the introducer, positioning the implantable wireless device adjacent to or near one or more excitable tissue in the patient, the one or more excitable tissue regulating a nerve activity associated with the urological disorder; and causing neural modulation of the one or more excitable tissue through one or more electrodes on the implantable wireless device.

The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.

The present invention relates to methods for the diagnosis and treatment of a urological disorder or urological disorders. Specifically, the present invention identifies the differential expression of Carboxypeptidase Z, identified as “8263” gene in tissues relating to urological disorder, relative to their expression in normal, or non-urological disorder disease states, and/or in response to manipulations relevant to a urological disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various urological diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a urological disorder or urological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of urological disorders.

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, nonalcoholic fatty liver disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

The invention provides pharmacological compositions comprising PDE-5 and PDE-4 inhibitors, alone or in combination, for the treatment of urological disorders comprising Benign Prostate Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS) and in particular irritative symptoms caused by BPH-induced bladder outlet obstruction (BOO). The invention also provides methods of screening for such PDE-5 and PDE-4 inhibitors for use, alone and in combination, in the preparation of medicaments for the treatment of said urological disorders.

The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I).

Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.

The present invention relates to novel 5-(Heterocyclyl)alkyl-N- (arylsulfonyl)indole compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. These compounds are useful in the treatment of various disorders that are related to 5-HT6 receptor functions. Specifically, the compounds of this invention are also useful in the treatment of various CNS disorders, hematological disorders, eating disorders, diseases associated with pain, respiratory diseases, genito-urological disorders, cardiovascular diseases and cancer.